Asuragen, Biogen Idec Sign Rx/Dx Co-development Pact | GenomeWeb

NEW YORK (GenomeWeb News) – Asuragen said today that it will work with Biogen Idec to develop a companion diagnostic test for a cancer drug.

Asuragen will use its RNA technologies to develop an assay that could help select which patients will benefit from a drug candidate that Biogen Idec now has in clinical development.

The Austin, Texas-based Asuragen currently offers its Signature Genetic Testing and Oncology Testing product lines, as well as its Armored RNA technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.